Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab alone or with ipilimumab versus ipilimumab in untreated advanced melanoma
NL-OMON53096Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Nivolumab monotherapy, Nivolumab + ipilimumab and Ipilimumab monotherapy (3 arms). Primary endpoints: Overall survival and Progression-free survival. Started Sep 2013; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON53096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53096.